IMUNON, Inc. reported a net loss of $3.8 million for Q3 2026, slightly higher than the previous year, while advancing its Phase 3 OVATION 3 trial for IMNN-001, a promising DNA-based immunotherapy for advanced ovarian cancer. The company highlighted positive Phase 2 data showing survival benefits and a strong safety profile, with ongoing collaboration with the National Cancer Institute to support development. Financially, IMUNON improved its position through a debt-for-equity exchange and plans to focus on executing the OVATION 3 trial to bring a new treatment option to patients. Cash and equivalents stood at $4 million as of September 30, 2026.
IMUNON's third quarter 2026 update comes as the health sector on Pluang shows mixed performance. For readers following health stocks, here is Pluang's market snapshot as of Nov 12, 2026 19:11 WIB: out of 150 priced US health stocks, 91 rose and 53 fell. Notable movers include MRVI at USD 7.94 with a 3.12% gain and a typical hold time of 18 days, TWST at USD 118.77 down 3.12% with 100% buy order activity, and INO at USD 1.43 down 3.05% with a typical hold time of 41 days.
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
Glider has introduced a global investing platform for tokenized stocks that operates permissionlessly, bypassing the SEC's Tokenized Securities Venues (TSVs) which 50 public companies recently rejected. Backed by major investors like a16z and Coinbas...
Tilray Brands announced that its subsidiaries 10 Barrel Brewing, Widmer Brothers Brewing, and Hop Valley Brewing are now the official craft beer partners of the Portland Trail Blazers. This partnership expands the availability of Oregon craft beers a...
Nexpu Ltd.'s subsidiary, Top Kingwin Hi Tech Inc., has finished delivering all 10,000 TK-D2C robots to Walkers Times International under a $4.8 million resale contract signed in 2025. The deliveries were completed in batches, with the final 5,000 uni...
